Structural basis for isoform-selective inhibition in nitric oxide synthase

Area of Science:

• Biochemistry
• Neuroscience
• Medicinal Chemistry

Background:

• Nitric oxide synthase (NOS) produces nitric oxide (NO), a signaling molecule with diverse physiological roles.
• Overproduction of NO by neuronal NOS (nNOS) contributes to tissue damage in neurodegenerative diseases.
• Developing selective nNOS inhibitors is crucial to avoid side effects associated with inhibiting endothelial NOS (eNOS).

Purpose of the Study:

• To develop drug candidates that specifically target nNOS over other NOS isoforms.
• To leverage structural and computational insights for designing isoform-selective inhibitors.
• To identify compounds with therapeutic potential for neurodegenerative conditions.

Main Methods:

• X-ray crystallography to determine NOS-inhibitor complex structures.
• Computational chemistry to analyze inhibitor protonation states and selectivity.
• Organic synthesis to create novel aminopyridine and double-headed inhibitor compounds.

Main Results:

• Developed aminopyridine compounds with 3800-fold selectivity for nNOS over eNOS.
• Identified key structural determinants of isoform selectivity, including a single amino acid difference and inhibitor chirality.
• Observed unexpected binding modes and the formation of a novel Zn(2+) site with double-headed inhibitors.

Conclusions:

• Subtle structural and dynamic differences in NOS isoforms can be exploited for highly selective inhibitor design.
• Aminopyridine compounds show promise as neuroprotective agents.
• This work provides a foundation for developing targeted therapies for nNOS-related neurological disorders.